p16INK4a status and response to induction low-dose fractionated radiation in advanced head and neck cancer

Natalie L. Silver; Susanne M. Arnold; John F. Gleason; Mahesh Kudrimoti; Yolanda Brill; Emily V. Dressler; Joseph Valentino

doi:10.1177/0003489415579220

p16INK4a status and response to induction low-dose fractionated radiation in advanced head and neck cancer

Natalie L. Silver, Susanne M. Arnold, John F. Gleason, Mahesh Kudrimoti, Yolanda Brill, Emily V. Dressler, Joseph Valentino

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Objective: To evaluate the impact of p16INK4a (p16) expression on clinical efficacy of induction low-dose fractionated radiation therapy (LDFRT) with concurrent chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Study Design: Historical cohort study. Setting: Tertiary medical center. Methods: A total of 66 Patients with locally advanced SCCHN were enrolled in 2 clinical trials using paclitaxel, carboplatin, and concurrent LDFRT induction therapy. Patients were evaluated for response to induction by a multidisciplinary team and then were given definitive treatment. Adequate tissue samples from the pretreatment biopsies of 42 individuals were identified and analyzed for p16 expression. Expression was correlated with clinical outcomes. Results: Of 42 tumors, 15 (35.7%) were positive for p16. Patients with p16-positive tumors had improved response to induction, but this was not statistically significant (P = .06). Five-year overall survival was 80% in p16-positive patients and 58% in p16-negative patients (P = .025). Conclusions: p16 Expression affects treatment response in patients treated with induction LDFRT with concurrent chemotherapy. This is similar to results reported for standard induction chemotherapy.

Original language	English
Pages (from-to)	714-720
Number of pages	7
Journal	Annals of Otology, Rhinology and Laryngology
Volume	124
Issue number	9
DOIs	https://doi.org/10.1177/0003489415579220
State	Published - Jan 1 2015

Bibliographical note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was in part supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through grant number UL1TR000117. Dr Dressler is supported by the National Center for Research Resources, UL1RR033173, and the National Center for Advancing Translational Sciences, UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent official views of the NIH. The initial clinical trial was supported in part by a grant from Bristol Myers Squibb.

Publisher Copyright:
© The Author(s) 2015.

Keywords

Chemotherapy
Head and neck squamous cell carcinoma
Human papillomavirus
Induction
Low-dose
P16
Radiotherapy

ASJC Scopus subject areas

Otorhinolaryngology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/0003489415579220

Cite this

@article{87c56a5493e741cfa0ec99ffc2d521d9,

title = "p16INK4a status and response to induction low-dose fractionated radiation in advanced head and neck cancer",

abstract = "Objective: To evaluate the impact of p16INK4a (p16) expression on clinical efficacy of induction low-dose fractionated radiation therapy (LDFRT) with concurrent chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Study Design: Historical cohort study. Setting: Tertiary medical center. Methods: A total of 66 Patients with locally advanced SCCHN were enrolled in 2 clinical trials using paclitaxel, carboplatin, and concurrent LDFRT induction therapy. Patients were evaluated for response to induction by a multidisciplinary team and then were given definitive treatment. Adequate tissue samples from the pretreatment biopsies of 42 individuals were identified and analyzed for p16 expression. Expression was correlated with clinical outcomes. Results: Of 42 tumors, 15 (35.7%) were positive for p16. Patients with p16-positive tumors had improved response to induction, but this was not statistically significant (P = .06). Five-year overall survival was 80% in p16-positive patients and 58% in p16-negative patients (P = .025). Conclusions: p16 Expression affects treatment response in patients treated with induction LDFRT with concurrent chemotherapy. This is similar to results reported for standard induction chemotherapy.",

keywords = "Chemotherapy, Head and neck squamous cell carcinoma, Human papillomavirus, Induction, Low-dose, P16, Radiotherapy",

author = "Silver, {Natalie L.} and Arnold, {Susanne M.} and Gleason, {John F.} and Mahesh Kudrimoti and Yolanda Brill and Dressler, {Emily V.} and Joseph Valentino",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was in part supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through grant number UL1TR000117. Dr Dressler is supported by the National Center for Research Resources, UL1RR033173, and the National Center for Advancing Translational Sciences, UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent official views of the NIH. The initial clinical trial was supported in part by a grant from Bristol Myers Squibb. Publisher Copyright: {\textcopyright} The Author(s) 2015.",

year = "2015",

month = jan,

day = "1",

doi = "10.1177/0003489415579220",

language = "English",

volume = "124",

pages = "714--720",

number = "9",

}

TY - JOUR

T1 - p16INK4a status and response to induction low-dose fractionated radiation in advanced head and neck cancer

AU - Silver, Natalie L.

AU - Arnold, Susanne M.

AU - Gleason, John F.

AU - Kudrimoti, Mahesh

AU - Brill, Yolanda

AU - Dressler, Emily V.

AU - Valentino, Joseph

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was in part supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through grant number UL1TR000117. Dr Dressler is supported by the National Center for Research Resources, UL1RR033173, and the National Center for Advancing Translational Sciences, UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent official views of the NIH. The initial clinical trial was supported in part by a grant from Bristol Myers Squibb. Publisher Copyright: © The Author(s) 2015.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: To evaluate the impact of p16INK4a (p16) expression on clinical efficacy of induction low-dose fractionated radiation therapy (LDFRT) with concurrent chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Study Design: Historical cohort study. Setting: Tertiary medical center. Methods: A total of 66 Patients with locally advanced SCCHN were enrolled in 2 clinical trials using paclitaxel, carboplatin, and concurrent LDFRT induction therapy. Patients were evaluated for response to induction by a multidisciplinary team and then were given definitive treatment. Adequate tissue samples from the pretreatment biopsies of 42 individuals were identified and analyzed for p16 expression. Expression was correlated with clinical outcomes. Results: Of 42 tumors, 15 (35.7%) were positive for p16. Patients with p16-positive tumors had improved response to induction, but this was not statistically significant (P = .06). Five-year overall survival was 80% in p16-positive patients and 58% in p16-negative patients (P = .025). Conclusions: p16 Expression affects treatment response in patients treated with induction LDFRT with concurrent chemotherapy. This is similar to results reported for standard induction chemotherapy.

AB - Objective: To evaluate the impact of p16INK4a (p16) expression on clinical efficacy of induction low-dose fractionated radiation therapy (LDFRT) with concurrent chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Study Design: Historical cohort study. Setting: Tertiary medical center. Methods: A total of 66 Patients with locally advanced SCCHN were enrolled in 2 clinical trials using paclitaxel, carboplatin, and concurrent LDFRT induction therapy. Patients were evaluated for response to induction by a multidisciplinary team and then were given definitive treatment. Adequate tissue samples from the pretreatment biopsies of 42 individuals were identified and analyzed for p16 expression. Expression was correlated with clinical outcomes. Results: Of 42 tumors, 15 (35.7%) were positive for p16. Patients with p16-positive tumors had improved response to induction, but this was not statistically significant (P = .06). Five-year overall survival was 80% in p16-positive patients and 58% in p16-negative patients (P = .025). Conclusions: p16 Expression affects treatment response in patients treated with induction LDFRT with concurrent chemotherapy. This is similar to results reported for standard induction chemotherapy.

KW - Chemotherapy

KW - Head and neck squamous cell carcinoma

KW - Human papillomavirus

KW - Induction

KW - Low-dose

KW - P16

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84942626653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942626653&partnerID=8YFLogxK

U2 - 10.1177/0003489415579220

DO - 10.1177/0003489415579220

M3 - Article

C2 - 25810339

AN - SCOPUS:84942626653

VL - 124

SP - 714

EP - 720

IS - 9

ER -

p16INK4a status and response to induction low-dose fractionated radiation in advanced head and neck cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this